A Crucial Step Toward Introducing Predictive Testing Services into Clinical Practice
Leiden, The Netherlands, 10 March 2026 — VitroScan is a Dutch biotech company developing predictive ex vivo micro‑tumor testing to help physicians make informed cancer treatment decisions. Today VitroScan announced that its laboratory operations are now operating under an ISO-15189 compliant quality management system. This internationally recognized standard sets the benchmark for excellence in medical laboratories, ensuring that every clinical sample analysis meets the highest levels of quality, reliability, and regulatory compliance.
“ISO‑15189 compliance is a major milestone that reflects the dedication of our entire team to the highest standards of clinical testing,” said Dr. Willemijn Vader, CEO of VitroScan. “It brings the trust and confidence that is needed when providing doctors and patients with predictive testing to support treatment decisions.”
What ISO‑15189 Means for VitroScan:
- Rigorous quality-management across all laboratory processes
- Traceability and documentation that meet global clinical standards
- High confidence in the predictive testing for partners, clinicians and patients
Recently, VitroScan published a landmark study in precision oncology demonstrating that its ex vivo micro‑tumor testing accurately predicts chemotherapy response for ovarian cancer patients. The study showed a clear separation between predicted chemotherapy‑resistant and chemotherapy‑sensitive patients. Predicted sensitive patients experiencing significantly longer times to disease progression.
Implementation of the ISO-15189 standard at VitroScan’s facilities clears the path for delivering consistent, high‑quality results for cancer patients across different cancer therapies including chemo, targeted and immunotherapies
The accomplishment stems from the relentless efforts of the VitroScan team. Special thanks to Biotech Booster for its financial and technical support, and to the collaborating clinicians and patient organisations.
About VitroScan
VitroScan is a private biotech company located at the Leiden Bio Science Park in The Netherlands. The company offers predictive testing solutions in oncology based on ex vivo micro-tumor testing. The assays generate highly translational, predictive data to support treatment decisions by physicians and to de-risk the clinical development of promising new therapies. The assays are currently available for research use only (RUO).
